Drug Type Small molecule drug |
Synonyms Zicronapine (USAN/INN), Zicronapine Succinate, zye-KRon-a-peen + [3] |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D1 receptor antagonists(Dopamine D1 receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H27ClN2 |
InChIKeyBYPMJBXPNZMNQD-PZJWPPBQSA-N |
CAS Registry170381-16-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10329 | Zicronapine | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 3 | CZ | 01 Apr 2011 | |
Schizophrenia | Phase 3 | EE | 01 Apr 2011 | |
Schizophrenia | Phase 3 | FI | 01 Apr 2011 | |
Schizophrenia | Phase 3 | FR | 01 Apr 2011 | |
Schizophrenia | Phase 3 | PL | 01 Apr 2011 |
Phase 2 | 46 | (Zicronapine Open-label 10 mg Daily) | cjonptvfjz(kwirrqibgv) = kuofwjxgex elryvrbcma (oraytxlder, euzomjcozd - mzcvhurevc) View more | - | 22 Mar 2016 | ||
(Zicronapine Basis Dose 10 mg Daily) | cjonptvfjz(kwirrqibgv) = exwukqemow elryvrbcma (oraytxlder, wtrcrfvllr - dewfgdbstl) View more |